{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T21:24:58Z","timestamp":1790803498460,"version":"4.1.0"},"reference-count":40,"publisher":"American Society of Hematology","issue":"1","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2015,12,5]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Atypical chronic myeloid leukemia (aCML) and chronic neutrophilic leukemia (CNL) are rare myeloid neoplasms defined largely by morphologic criteria. The discovery of CSF3R mutations in aCML and CNL have prompted a more comprehensive genetic profiling of these disorders. These studies have revealed aCML to be a genetically more heterogeneous disease than CNL, however, several groups have reported that SETBP1 and ASXL1 mutations occur at a high frequency and carry prognostic value in both diseases. We also report a novel finding\u2014our study reveals a high frequency of U2AF1 mutations at codon Q157 associated with CSF3R mutant myeloid neoplasms. Collectively, these findings will refine the WHO diagnostic criteria of aCML and CNL and help us understand the genetic lesions and dysregulated signaling pathways contributing to disease development. Novel therapies that emerge from these genetic findings will need to be investigated in the setting of a clinical trial to determine the safety and efficacy of targeting various oncogenic drivers, such as JAK1\/2 inhibition in CSF3R-T618I\u2013positive aCML and CNL. In summary, recent advances in the genetic characterization of CNL and aCML are instrumental toward the development of new lines of therapy for these rare leukemias that lack an established standard of care and are historically associated with a poor prognosis.<\/jats:p>","DOI":"10.1182\/asheducation-2015.1.264","type":"journal-article","created":{"date-parts":[[2016,9,15]],"date-time":"2016-09-15T15:23:25Z","timestamp":1473953005000},"page":"264-271","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":41,"title":["What's different about atypical CML and chronic neutrophilic leukemia?"],"prefix":"10.1182","volume":"2015","author":[{"given":"Kim-Hien T.","family":"Dao","sequence":"first","affiliation":[{"name":"Knight Cancer Institute, Hematology and Medical Oncology, Oregon Health & Science University, Portland, OR; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey W.","family":"Tyner","sequence":"additional","affiliation":[{"name":"Knight Cancer Institute, Department of Cell, Development and Cancer Biology, Oregon Health & Science University, Portland, OR"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"issue":"19","key":"2019111705283732500_B1","doi-asserted-by":"crossref","first-page":"1781","DOI":"10.1056\/NEJMoa1214514","article-title":"Oncogenic CSF3R mutations in chronic neutrophilic leukemia and atypical CML","volume":"368","author":"Maxson","year":"2013","journal-title":"N Engl J Med"},{"issue":"9","key":"2019111705283732500_B2","doi-asserted-by":"crossref","first-page":"1870","DOI":"10.1038\/leu.2013.122","article-title":"CSF3R T618I is a highly prevalent and specific mutation in chronic neutrophilic leukemia","volume":"27","author":"Pardanani","year":"2013","journal-title":"Leukemia"},{"key":"2019111705283732500_B3","volume-title":"WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues","author":"Swerdlow","year":"2008","edition":"Fourth Edition"},{"issue":"17","key":"2019111705283732500_B4","doi-asserted-by":"crossref","first-page":"2645","DOI":"10.1182\/blood-2014-02-553800","article-title":"Atypical chronic myeloid leukemia is clinically distinct from unclassifiable myelodysplastic\/myeloproliferative neoplasms","volume":"123","author":"Wang","year":"2014","journal-title":"Blood"},{"issue":"12","key":"2019111705283732500_B5","doi-asserted-by":"crossref","first-page":"e244","DOI":"10.3324\/haematol.2014.113159","article-title":"Specific molecular mutation patterns delineate chronic neutrophilic leukemia, atypical chronic myeloid leukemia, and chronic myelomonocytic leukemia","volume":"99","author":"Meggendorfer","year":"2014","journal-title":"Haematologica"},{"issue":"1","key":"2019111705283732500_B6","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1038\/ng.2495","article-title":"Recurrent SETBP1 mutations in atypical chronic myeloid leukemia","volume":"45","author":"Piazza","year":"2013","journal-title":"Nat Genet"},{"key":"2019111705283732500_B7","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1186\/s13045-014-0077-1","article-title":"CSF3R, SETBP1 and CALR mutations in chronic neutrophilic leukemia","volume":"7","author":"Cui","year":"2014","journal-title":"J Hematol Oncol"},{"issue":"2","key":"2019111705283732500_B8","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1182\/blood-2011-01-328955","article-title":"The Myeloproliferative Neoplasm Symptom Assessment Form (MPN-SAF): international prospective validation and reliability trial in 402 patients","volume":"118","author":"Scherber","year":"2011","journal-title":"Blood"},{"issue":"4","key":"2019111705283732500_B9","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1007\/BF02982088","article-title":"Severe bleeding tendency caused by leukemic infiltration and destruction of vascular walls in chronic neutrophilic leukemia","volume":"74","author":"Noguchi","year":"2001","journal-title":"Int J Hematol"},{"issue":"11","key":"2019111705283732500_B10","first-page":"1566","article-title":"Identification of risk factors in atypical chronic myeloid leukemia","volume":"91","author":"Breccia","year":"2006","journal-title":"Haematologica"},{"issue":"2","key":"2019111705283732500_B11","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1038\/sj.leu.2403562","article-title":"WHO-defined chronic neutrophilic leukemia: a long-term analysis of 12 cases and a critical review of the literature","volume":"19","author":"Elliott","year":"2005","journal-title":"Leukemia"},{"issue":"8","key":"2019111705283732500_B12","doi-asserted-by":"crossref","first-page":"1701","DOI":"10.1084\/jem.20090693","article-title":"An activating mutation in the CSF3R gene induces a hereditary chronic neutrophilia","volume":"206","author":"Plo","year":"2009","journal-title":"J Exp Med"},{"issue":"22","key":"2019111705283732500_B13","doi-asserted-by":"crossref","first-page":"3628","DOI":"10.1182\/blood-2013-06-509976","article-title":"The CSF3R T618I mutation causes a lethal neutrophilic neoplasia in mice that is responsive to therapeutic JAK inhibition","volume":"122","author":"Fleischman","year":"2013","journal-title":"Blood"},{"issue":"2","key":"2019111705283732500_B14","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1097\/MOH.0000000000000114","article-title":"Chronic neutrophilic leukemia: novel mutations and their impact on clinical practice","volume":"22","author":"Tefferi","year":"2015","journal-title":"Curr Opin Hematol"},{"issue":"7","key":"2019111705283732500_B15","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1002\/ajh.24031","article-title":"ASXL1 mutations are frequent and prognostically detrimental in CSF3R-mutated chronic neutrophilic leukemia","volume":"90","author":"Elliott","year":"2015","journal-title":"Am J Hematol"},{"key":"2019111705283732500_B16","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1186\/1756-8722-5-12","article-title":"Mutations in ASXL1 are associated with poor prognosis across the spectrum of malignant myeloid diseases","volume":"5","author":"Gelsi-Boyer","year":"2012","journal-title":"J Hematol Oncol"},{"issue":"1","key":"2019111705283732500_B17","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1182\/blood-2009-07-230698","article-title":"Loss-of-function additional sex combs like 1 mutations disrupt hematopoiesis but do not cause severe myelodysplasia or leukemia","volume":"115","author":"Fisher","year":"2010","journal-title":"Blood"},{"issue":"8","key":"2019111705283732500_B18","doi-asserted-by":"crossref","first-page":"942","DOI":"10.1038\/ng.2696","article-title":"Somatic SETBP1 mutations in myeloid malignancies","volume":"45","author":"Makishima","year":"2013","journal-title":"Nat Genet"},{"issue":"1","key":"2019111705283732500_B19","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1101\/gr.181016.114","article-title":"U2AF1 mutations alter splice site recognition in hematological malignancies","volume":"25","author":"Ilagan","year":"2015","journal-title":"Genome Res"},{"issue":"10","key":"2019111705283732500_B20","doi-asserted-by":"crossref","first-page":"1707","DOI":"10.1182\/blood-2013-05-500959","article-title":"The new genetics of chronic neutrophilic leukemia and atypical CML: implications for diagnosis and treatment","volume":"122","author":"Gotlib","year":"2013","journal-title":"Blood"},{"issue":"3","key":"2019111705283732500_B21","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/S1470-2045(09)70003-8","article-title":"Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study","volume":"10","author":"Fenaux","year":"2009","journal-title":"Lancet Oncol"},{"issue":"24","key":"2019111705283732500_B22","doi-asserted-by":"crossref","first-page":"6392","DOI":"10.1182\/blood-2011-04-348144","article-title":"TNFalpha facilitates clonal expansion of JAK2V617F positive cells in myeloproliferative neoplasms","volume":"118","author":"Fleischman","year":"2011","journal-title":"Blood"},{"issue":"19","key":"2019111705283732500_B23","doi-asserted-by":"crossref","first-page":"3335","DOI":"10.1182\/blood-2013-02-485607","article-title":"Autocrine TNF-alpha production supports CML stem and progenitor cell survival and enhances their proliferation","volume":"122","author":"Gallipoli","year":"2013","journal-title":"Blood"},{"issue":"37","key":"2019111705283732500_B24","doi-asserted-by":"crossref","first-page":"33968","DOI":"10.1074\/jbc.M203350200","article-title":"Calpain-mediated X-linked inhibitor of apoptosis degradation in neutrophil apoptosis and its impairment in chronic neutrophilic leukemia","volume":"277","author":"Kobayashi","year":"2002","journal-title":"J Biol Chem"},{"issue":"3","key":"2019111705283732500_B25","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1111\/ejh.12223","article-title":"Postallogeneic monitoring with molecular markers detected by pretransplant next-generation or Sanger sequencing predicts clinical relapse in patients with myelodysplastic\/myeloproliferative neoplasms","volume":"92","author":"Fu","year":"2014","journal-title":"Eur J Haematol"},{"issue":"3","key":"2019111705283732500_B26","doi-asserted-by":"crossref","first-page":"178","DOI":"10.5045\/br.2013.48.3.178","article-title":"Allogeneic hematopoietic cell transplantation in adult patients with myelodysplastic\/myeloproliferative neoplasms","volume":"48","author":"Lim","year":"2013","journal-title":"Blood Res"},{"issue":"12","key":"2019111705283732500_B27","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1038\/sj.bmt.1704686","article-title":"Outcome of hematopoietic stem cell transplantation in patients with atypical chronic myeloid leukemia","volume":"34","author":"Koldehoff","year":"2004","journal-title":"Bone Marrow Transplant"},{"issue":"6","key":"2019111705283732500_B28","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1038\/bmt.2014.35","article-title":"The CSF3R T618I mutation as a disease-specific marker of atypical CML post allo-SCT","volume":"49","author":"Langabeer","year":"2014","journal-title":"Bone Marrow Transplant"},{"issue":"25","key":"2019111705283732500_B29","doi-asserted-by":"crossref","first-page":"2379","DOI":"10.1056\/NEJMoa1311347","article-title":"Somatic mutations of calreticulin in myeloproliferative neoplasms","volume":"369","author":"Klampfl","year":"2013","journal-title":"N Engl J Med"},{"issue":"24","key":"2019111705283732500_B30","doi-asserted-by":"crossref","first-page":"6182","DOI":"10.1182\/blood-2008-12-194548","article-title":"Frequent CBL mutations associated with 11q acquired uniparental disomy in myeloproliferative neoplasms","volume":"113","author":"Grand","year":"2009","journal-title":"Blood"},{"issue":"7257","key":"2019111705283732500_B31","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1038\/nature08240","article-title":"Gain-of-function of mutated C-CBL tumour suppressor in myeloid neoplasms","volume":"460","author":"Sanada","year":"2009","journal-title":"Nature"},{"issue":"8","key":"2019111705283732500_B32","doi-asserted-by":"crossref","first-page":"992","DOI":"10.1101\/gad.1651408","article-title":"The E3 ubiquitin ligase c-Cbl restricts development and functions of hematopoietic stem cells","volume":"22","author":"Rathinam","year":"2008","journal-title":"Genes Dev"},{"issue":"37","key":"2019111705283732500_B33","doi-asserted-by":"crossref","first-page":"16274","DOI":"10.1073\/pnas.1007575107","article-title":"Rapidly fatal myeloproliferative disorders in mice with deletion of Casitas B-cell lymphoma (Cbl) and Cbl-b in hematopoietic stem cells","volume":"107","author":"Naramura","year":"2010","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"3","key":"2019111705283732500_B34","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1182\/blood-2014-06-579466","article-title":"Recurrent ETNK1 mutations in atypical chronic myeloid leukemia","volume":"125","author":"Gambacorti-Passerini","year":"2015","journal-title":"Blood"},{"issue":"3","key":"2019111705283732500_B35","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1242\/dmm.006817","article-title":"Mouse models of myeloproliferative neoplasms: JAK of all grades","volume":"4","author":"Li","year":"2011","journal-title":"Dis Model Mech"},{"issue":"1","key":"2019111705283732500_B36","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1128\/MCB.01153-06","article-title":"Neoplasia driven by mutant c-KIT is mediated by intracellular, not plasma membrane, receptor signaling","volume":"27","author":"Xiang","year":"2007","journal-title":"Mol Cell Biol"},{"issue":"7","key":"2019111705283732500_B37","doi-asserted-by":"crossref","first-page":"e270","DOI":"10.1371\/journal.pmed.0030270","article-title":"MPLW515L is a novel somatic activating mutation in myelofibrosis with myeloid metaplasia","volume":"3","author":"Pikman","year":"2006","journal-title":"PLoS Med"},{"issue":"8","key":"2019111705283732500_B38","doi-asserted-by":"crossref","first-page":"2629","DOI":"10.1182\/blood.V74.8.2629.2629","article-title":"Mutations of the ras protooncogenes in chronic myelogenous leukemia: a high frequency of ras mutations in bcr\/abl rearrangement-negative chronic myelogenous leukemia","volume":"74","author":"Cogswell","year":"1989","journal-title":"Blood"},{"issue":"7","key":"2019111705283732500_B39","doi-asserted-by":"crossref","first-page":"2349","DOI":"10.1182\/blood-2004-08-009498","article-title":"Oncogenic NRAS rapidly and efficiently induces CMML- and AML-like diseases in mice","volume":"108","author":"Parikh","year":"2006","journal-title":"Blood"},{"key":"2019111705283732500_B40","article-title":"Recurrent KIT D816V mutation in atypical chronic myeloid leukemia [abstract]","volume":"124","author":"Redaelli","year":"2014","journal-title":"Blood (ASH Annual Meeting Abstracts)"}],"updated-by":[{"DOI":"10.1182\/asheducation-2016.1.717","type":"erratum","label":"Erratum","source":"publisher","updated":{"date-parts":[[2016,12,2]],"date-time":"2016-12-02T00:00:00Z","timestamp":1480636800000}}],"container-title":["Hematology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/hematology\/article-pdf\/2015\/1\/264\/1249820\/bep00115000264.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/hematology\/article-pdf\/2015\/1\/264\/1249820\/bep00115000264.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,11,17]],"date-time":"2019-11-17T10:28:54Z","timestamp":1573986534000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/hematology\/article\/2015\/1\/264\/20593\/Whats-different-about-atypical-CML-and-chronic"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,12,5]]},"references-count":40,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2015,12,5]]}},"URL":"https:\/\/doi.org\/10.1182\/asheducation-2015.1.264","relation":{"erratum":[{"id-type":"doi","id":"10.1182\/asheducation-2016.1.717","asserted-by":"object"}]},"ISSN":["1520-4391","1520-4383"],"issn-type":[{"value":"1520-4391","type":"print"},{"value":"1520-4383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,12,5]]}}}